Romidepsin (Synonyms: 羅米地辛; FK 228; FR 901228; NSC 630176)

目錄號: HY-15149 純度: 99.87%: FAQs
Data Sheet SDS COA 產品使用指南技術支持

Romidepsin (FK 228) 是具有抗腫瘤活性的組蛋白去乙?；?(HDAC) 抑制劑，抑制 HDAC1，HDAC2，HDAC4 和 HDAC6，IC₅₀ 值分別為 36 nM，47 nM，510 nM 和 1.4 μM。Romidepsin (FK 228) 由紫色桿菌產生，誘導 G2/M 細胞周期阻滯和凋亡 (apoptosis)。

MCE 的所有產品僅用作科學研究或藥證申報，我們不為任何個人用途提供產品和服務

Romidepsin Chemical Structure

CAS No. : 128517-07-7

1. 客戶無需承擔相應的運輸費用。

2. 同一機構（單位）同一產品試用裝僅限申領一次，同一機構（單位）一年內

可免費申領三個不同產品的試用裝。

3. 試用裝只面向終端客戶。

規(guī)格	價格	是否有貨
1 mg	￥1000	In-stock
5 mg	￥2900	In-stock
10 mg	￥4950	In-stock
25 mg	現(xiàn)貨	詢價
50 mg	現(xiàn)貨	詢價
100 mg		詢價
200 mg		詢價

or 大包裝詢價

* Please select Quantity before adding items.

Customer Review

MCE 顧客使用本產品發(fā)表的 51 篇科研文獻

•Cancer Cell. 2023 Mar 13;41(3):602-619.e11. [Abstract]
•Cell Rep Med. 2024 Sep 27:101770. [Abstract]
•EBioMedicine. 2022 Dec 31;87:104420. [Abstract]
•Clin Transl Med. 2022 Jan;12(1):e703. [Abstract]
•Theranostics. 2021 Mar 20;11(11):5605-5619. [Abstract]
•Cancer Res. 2020 Oct 15;80(20):4426-4438. [Abstract]

•Cancer Res. 2016 Dec 1;76(23):7001-7011. [Abstract]
•Cancer Lett. 2022 Nov 30;216028. [Abstract]
•Acta Pharmacol Sin. 2021 Dec 10. [Abstract]
•Cell Death Dis. 2020 Sep 15;11(9):753. [Abstract]
•Cell Death Dis. 2020 Sep 18;11(9):778. [Abstract]
•J Med Chem. 2024 Aug 15. [Abstract]
•Apoptosis. 2020 Oct;25(9-10):697-714. [Abstract]
•PLoS Pathog. 2018 Sep 13;14(9):e1007267. [Abstract]
•J Med Chem. 2015 Nov 12;58(21):8638-46. [Abstract]
•Neoplasia. 2025 Jan 25:60:101121. [Abstract]
•Eur J Pharm Sci. 2025 Feb 12:107043. [Abstract]
•Cell Rep Methods. 2023 Oct 23;3(10):100599. [Abstract]
•Mol Med. 2024 May 31.
•Clin Transl Immunology. 2024 Mar 25;13(3):e1500. [Abstract]
•Clin Epigenetics. 2023 Feb 6;15(1):19. [Abstract]
•Commun Biol. 2021 Oct 29;4(1):1235. [Abstract]
•Stem Cells. 2021 Jun 28. [Abstract]
•Virus Res. 2020, 198260.
•Cells. 2020 Jul 10;9(7):1661. [Abstract]
•Mol Med. 2020 Jun 9;26(1):56. [Abstract]
•Cancers. 2019 Sep 7;11(9):1327. [Abstract]
•Virus Res. 2018 Apr 2;249:69-75. [Abstract]
•ACS Med Chem Lett. 2018 Feb 6;9(3):268-273. [Abstract]
•Epigenetics Chromatin. 2023 Apr 19;16(1):11. [Abstract]
•Neurooncol Adv. 17 July 2021.
•Mol Med Rep. 2021 Apr 19.
•Toxicol Sci. 2019 Jul 31;kfz163. [Abstract]
•J Pharmacol Exp Ther. 2019 Sep;370(3):490-503. [Abstract]
•Exp Cell Res. 2018 Dec 15;373(1-2):211-220. [Abstract]
•Neurosci Lett. 2017 May 12;653:12-18. [Abstract]
•PLoS One. 2016 Jun 24;11(6):e0158294. [Abstract]
•bioRxiv. 2024 September 11.
•bioRxiv. 2024 September 20.
•Columbia University. 2023 Aug 23.
•Cancer Res Commun. 2023 Jul 19.
•Research Square Print. 2023 Mar 9.
•Authorea. 2023 Feb 17.
•Asian Pac J Cancer Prev. 2023 Jan 1;24(1):185-194. [Abstract]
•Research Square Print. September 13th, 2022.
•Uppsala University. Department of Pharmaceutical Biosciences. 2022 Feb.
•bioRxiv. April 22, 2021.
•Università degli Studi di CAGLIARI. Dipartimento di Scienze Biomediche. 2021 May.
•Research Square Preprint. 2021 May.
•Methods Mol Biol. 2018;1711:351-398. [Abstract]
•Oncotarget. 2017 Apr 18;8(16):26637-26647. [Abstract]

Cell Viability Assay

: Romidepsin purchased from MCE. Usage Cited in: Cancer Cell. 2023 Mar 13;41(3):602-619.e11. [Abstract]; The triple combination of E + R + iC significantly decreases tumor volume compared with double combinations, in mice. E: enzalutamide (30 mg/kg; p.o.; single daily for 10 days); R: Romidepsin (0.3 mg/kg; i.p.; single daily for 10 days); iC: CXCR2 inhibitor.

: Romidepsin purchased from MCE. Usage Cited in: PLoS Pathog. 2018 Sep 13;14(9):e1007267. [Abstract]; Immunoblot analysis for vIL-6, ORF45, or actin is performed on lysates from BCBL-1 cells treated with NaB+TPA, Romidepsin or LBH589.

: Romidepsin purchased from MCE. Usage Cited in: Neurosci Lett. 2017 May 12;653:12-18. [Abstract]; Romidepsin increases histone acetylation in SH-SY5Y neuroblastoma cells. Western blots of pAcH3 and β-actin levels in SH-SY5Y cells cultured for 24 h with 0-40 nM of Romidepsin. 20 nM and 40 nM Romidepsin significantly increase the levels of pAcH3 relative to control, which is measured by densitometric quantification of pAcH3 protein levels relative to β-actin loading control.

Romidepsin 相關產品

•相關化合物庫:

•同靶點產品:

•同靶點蛋白產品:

查看 HDAC 亞型特異性產品:

查看所有亞型

HDAC HDAC1 HDAC2 HDAC3 HDAC4 HDAC5 HDAC6 HDAC7 HDAC8 HDAC9 HDAC10 HDAC11 HD1 HD2

生物活性
純度 & 產品資料
參考文獻

生物活性

Romidepsin (FK 228) is a Histone deacetylase (HDAC) inhibitor with anti-tumor activities. Romidepsin (FK 228) inhibits HDAC1, HDAC2, HDAC4, and HDAC6 with IC₅₀s of 36 nM, 47 nM, 510 nM and 1.4 μM, respectively^[1]. Romidepsin (FK 228) is produced by Chromobacterium violaceum, induces cell G2/M phase arrest and apoptosis^[2].

IC₅₀ & Target^[1]

HDAC1

36 nM (IC₅₀)

HDAC2

47 nM (IC₅₀)

HDAC4

510 nM (IC₅₀)

HDAC6

14000 nM (IC₅₀)

細胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A549	GI₅₀	2.6 nM Compound: 5, FK228	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 24589486]
A549	GI₅₀	2.6 nM Compound: 1, FK228	Growth inhibition of human A549 cells by sulforhodamine B colorimetric method Growth inhibition of human A549 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
ACHN	GI₅₀	20 nM Compound: 5, FK228	Cytotoxicity against human ACHN cells by SRB assay Cytotoxicity against human ACHN cells by SRB assay	[PMID: 24589486]
ACHN	GI₅₀	20 nM Compound: 1, FK228	Growth inhibition of human ACHN cells by sulforhodamine B colorimetric method Growth inhibition of human ACHN cells by sulforhodamine B colorimetric method	[PMID: 23313638]
DMS-114	GI₅₀	3.6 nM Compound: 5, FK228	Cytotoxicity against human DMS114 cells by SRB assay Cytotoxicity against human DMS114 cells by SRB assay	[PMID: 24589486]
DMS-114	GI₅₀	3.6 nM Compound: 1, FK228	Growth inhibition of human DMS114 cells by sulforhodamine B colorimetric method Growth inhibition of human DMS114 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
DMS-273	GI₅₀	5.8 nM Compound: 5, FK228	Cytotoxicity against human DMS273 cells by SRB assay Cytotoxicity against human DMS273 cells by SRB assay	[PMID: 24589486]
DMS-273	GI₅₀	5.8 nM Compound: 1, FK228	Growth inhibition of human DMS273 cells by sulforhodamine B colorimetric method Growth inhibition of human DMS273 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
DU-145	GI₅₀	2.55 nM Compound: 1, FK228	Antiproliferative activity against human DU145 cells after 72 hrs by CCK8 assay Antiproliferative activity against human DU145 cells after 72 hrs by CCK8 assay	[PMID: 26331334]
DU-145	GI₅₀	6 nM Compound: 5, FK228	Cytotoxicity against human DU145 cells by SRB assay Cytotoxicity against human DU145 cells by SRB assay	[PMID: 24589486]
DU-145	GI₅₀	6 nM Compound: 1, FK228	Growth inhibition of human DU145 cells by sulforhodamine B colorimetric method Growth inhibition of human DU145 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
HCC 2998	GI₅₀	3.1 nM Compound: 5, FK228	Cytotoxicity against human HCC2998 cells by SRB assay Cytotoxicity against human HCC2998 cells by SRB assay	[PMID: 24589486]
HCC 2998	GI₅₀	3.1 nM Compound: 1, FK228	Growth inhibition of human HCC2998 cells by sulforhodamine B colorimetric method Growth inhibition of human HCC2998 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
HCT-116	IC₅₀	0.028 μM Compound: Romidepsin	Antiproliferative activity against human HCT116 cells assessed as cell viability incubated for 72 hrs by coulter counter method Antiproliferative activity against human HCT116 cells assessed as cell viability incubated for 72 hrs by coulter counter method	[PMID: 26481659]
HCT-116	IC₅₀	3 nM Compound: FK228	Antiproliferative activity against human HCT116 cells after 48 hrs in presence of DTT by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs in presence of DTT by MTT assay	[PMID: 25147612]
HCT-116	GI₅₀	3.1 nM Compound: 5, FK228	Cytotoxicity against human HCT116 cells by SRB assay Cytotoxicity against human HCT116 cells by SRB assay	[PMID: 24589486]
HCT-116	GI₅₀	3.1 nM Compound: 1, FK228	Growth inhibition of human HCT116 cells by sulforhodamine B colorimetric method Growth inhibition of human HCT116 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
HCT-15	GI₅₀	450 nM Compound: 5, FK228	Cytotoxicity against human HCT15 cells by SRB assay Cytotoxicity against human HCT15 cells by SRB assay	[PMID: 24589486]
HCT-15	GI₅₀	450 nM Compound: 1, FK228	Growth inhibition of human HCT15 cells by sulforhodamine B colorimetric method Growth inhibition of human HCT15 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
HT-29	GI₅₀	3.3 nM Compound: 5, FK228	Cytotoxicity against human HT-29 cells by SRB assay Cytotoxicity against human HT-29 cells by SRB assay	[PMID: 24589486]
HT-29	GI₅₀	3.3 nM Compound: 1, FK228	Growth inhibition of human HT-29 cells by sulforhodamine B colorimetric method Growth inhibition of human HT-29 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
IGROV-1	IC₅₀	0.08 μM Compound: Romidepsin	Antiproliferative activity against human IGROV1/Pt1 cells assessed as cell viability incubated for 72 hrs by coulter counter method Antiproliferative activity against human IGROV1/Pt1 cells assessed as cell viability incubated for 72 hrs by coulter counter method	[PMID: 26481659]
IGROV-1	IC₅₀	0.22 μM Compound: Romidepsin	Antiproliferative activity against human IGROV1 cells assessed as cell viability incubated for 72 hrs by coulter counter method Antiproliferative activity against human IGROV1 cells assessed as cell viability incubated for 72 hrs by coulter counter method	[PMID: 26481659]
KM12	GI₅₀	3.4 nM Compound: 5, FK228	Cytotoxicity against human KM12 cells by SRB assay Cytotoxicity against human KM12 cells by SRB assay	[PMID: 24589486]
KM12	GI₅₀	3.4 nM Compound: 1, FK228	Growth inhibition of human KM12 cells by sulforhodamine B colorimetric method Growth inhibition of human KM12 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
LOX IMVI	GI₅₀	2.5 nM Compound: 5, FK228	Cytotoxicity against human LOXIMVI cells by SRB assay Cytotoxicity against human LOXIMVI cells by SRB assay	[PMID: 24589486]
LOX IMVI	GI₅₀	2.5 nM Compound: 1, FK228	Growth inhibition of human LOXIMVI cells by sulforhodamine B colorimetric method Growth inhibition of human LOXIMVI cells by sulforhodamine B colorimetric method	[PMID: 23313638]
MCF7	GI₅₀	4.2 nM Compound: 5, FK228	Cytotoxicity against human MCF7 cells by SRB assay Cytotoxicity against human MCF7 cells by SRB assay	[PMID: 24589486]
MCF7	GI₅₀	4.2 nM Compound: 1, FK228	Growth inhibition of human MCF7 cells by sulforhodamine B colorimetric method Growth inhibition of human MCF7 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
MDA-MB-231	GI₅₀	5.5 nM Compound: 5, FK228	Cytotoxicity against human MDA-MB-231 cells by SRB assay Cytotoxicity against human MDA-MB-231 cells by SRB assay	[PMID: 24589486]
MDA-MB-231	GI₅₀	5.5 nM Compound: 1, FK228	Growth inhibition of human MDA-MB-231 cells by sulforhodamine B colorimetric method Growth inhibition of human MDA-MB-231 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
MKN-1	GI₅₀	3.2 nM Compound: 5, FK228	Cytotoxicity against human MKN1 cells by SRB assay Cytotoxicity against human MKN1 cells by SRB assay	[PMID: 24589486]
MKN-1	GI₅₀	3.2 nM Compound: 1, FK228	Growth inhibition of human MKN1 cells by sulforhodamine B colorimetric method Growth inhibition of human MKN1 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
MKN-28	GI₅₀	17 nM Compound: 5, FK228	Cytotoxicity against human MKN28 cells by SRB assay Cytotoxicity against human MKN28 cells by SRB assay	[PMID: 24589486]
MKN-28	GI₅₀	17 nM Compound: 1, FK228	Growth inhibition of human MKN28 cells by sulforhodamine B colorimetric method Growth inhibition of human MKN28 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
MKN-45	GI₅₀	14 nM Compound: 5, FK228	Cytotoxicity against human MKN45 cells by SRB assay Cytotoxicity against human MKN45 cells by SRB assay	[PMID: 24589486]
MKN-45	GI₅₀	14 nM Compound: 1, FK228	Growth inhibition of human MKN45 cells by sulforhodamine B colorimetric method Growth inhibition of human MKN45 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
MKN-7	GI₅₀	4.9 nM Compound: 5, FK228	Cytotoxicity against human MKN7 cells by SRB assay Cytotoxicity against human MKN7 cells by SRB assay	[PMID: 24589486]
MKN-7	GI₅₀	4.9 nM Compound: 1, FK228	Growth inhibition of human MKN7 cells by sulforhodamine B colorimetric method Growth inhibition of human MKN7 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
MKN-74	GI₅₀	3 nM Compound: 5, FK228	Cytotoxicity against human MKN74 cells by SRB assay Cytotoxicity against human MKN74 cells by SRB assay	[PMID: 24589486]
MKN-74	GI₅₀	3 nM Compound: 1, FK228	Growth inhibition of human MKN74 cells by sulforhodamine B colorimetric method Growth inhibition of human MKN74 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
MOLT-4	GI₅₀	2.06 nM Compound: 1, FK228	Antiproliferative activity against human MOLT4 cells after 72 hrs by CCK8 assay Antiproliferative activity against human MOLT4 cells after 72 hrs by CCK8 assay	[PMID: 26331334]
NCI-H226	GI₅₀	8.9 nM Compound: 5, FK228	Cytotoxicity against human NCI-H226 cells by SRB assay Cytotoxicity against human NCI-H226 cells by SRB assay	[PMID: 24589486]
NCI-H226	GI₅₀	8.9 nM Compound: 1, FK228	Growth inhibition of human NCI-H226 cells by sulforhodamine B colorimetric method Growth inhibition of human NCI-H226 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
NCI-H23	GI₅₀	4.6 nM Compound: 5, FK228	Cytotoxicity against human NCI-H23 cells by SRB assay Cytotoxicity against human NCI-H23 cells by SRB assay	[PMID: 24589486]
NCI-H23	GI₅₀	4.6 nM Compound: 1, FK228	Growth inhibition of human NCI-H23 cells by sulforhodamine B colorimetric method Growth inhibition of human NCI-H23 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
NCI-H460	GI₅₀	3 nM Compound: 5, FK228	Cytotoxicity against human NCI-H460 cells by SRB assay Cytotoxicity against human NCI-H460 cells by SRB assay	[PMID: 24589486]
NCI-H460	GI₅₀	3 nM Compound: 1, FK228	Growth inhibition of human NCI-H460 cells by sulforhodamine B colorimetric method Growth inhibition of human NCI-H460 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
NCI-H522	GI₅₀	1.8 nM Compound: 5, FK228	Cytotoxicity against human NCI-H522 cells by SRB assay Cytotoxicity against human NCI-H522 cells by SRB assay	[PMID: 24589486]
NCI-H522	GI₅₀	1.8 nM Compound: 1, FK228	Growth inhibition of human NCI-H522 cells by sulforhodamine B colorimetric method Growth inhibition of human NCI-H522 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
OVCAR-3	GI₅₀	4.6 nM Compound: 5, FK228	Cytotoxicity against human OVCAR3 cells by SRB assay Cytotoxicity against human OVCAR3 cells by SRB assay	[PMID: 24589486]
OVCAR-3	GI₅₀	4.6 nM Compound: 1, FK228	Growth inhibition of human OVCAR3 cells by sulforhodamine B colorimetric method Growth inhibition of human OVCAR3 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
OVCAR-4	GI₅₀	20 nM Compound: 5, FK228	Cytotoxicity against human OVCAR4 cells by SRB assay Cytotoxicity against human OVCAR4 cells by SRB assay	[PMID: 24589486]
OVCAR-4	GI₅₀	20 nM Compound: 1, FK228	Growth inhibition of human OVCAR4 cells by sulforhodamine B colorimetric method Growth inhibition of human OVCAR4 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
OVCAR-5	GI₅₀	2.8 nM Compound: 5, FK228	Cytotoxicity against human OVCAR5 cells by SRB assay Cytotoxicity against human OVCAR5 cells by SRB assay	[PMID: 24589486]
OVCAR-5	GI₅₀	2.8 nM Compound: 1, FK228	Growth inhibition of human OVCAR5 cells by sulforhodamine B colorimetric method Growth inhibition of human OVCAR5 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
OVCAR-8	GI₅₀	5.5 nM Compound: 5, FK228	Cytotoxicity against human OVCAR8 cells by SRB assay Cytotoxicity against human OVCAR8 cells by SRB assay	[PMID: 24589486]
OVCAR-8	GI₅₀	5.5 nM Compound: 1, FK228	Growth inhibition of human OVCAR8 cells by sulforhodamine B colorimetric method Growth inhibition of human OVCAR8 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
PC-3	GI₅₀	18 nM Compound: 5, FK228	Cytotoxicity against human PC3 cells by SRB assay Cytotoxicity against human PC3 cells by SRB assay	[PMID: 24589486]
PC-3	GI₅₀	18 nM Compound: 1, FK228	Growth inhibition of human PC3 cells by sulforhodamine B colorimetric method Growth inhibition of human PC3 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
RXF 631	GI₅₀	6.6 nM Compound: 5, FK228	Cytotoxicity against human RXF631L cells by SRB assay Cytotoxicity against human RXF631L cells by SRB assay	[PMID: 24589486]
RXF 631	GI₅₀	6.6 nM Compound: 1, FK228	Growth inhibition of human RXF631L cells by sulforhodamine B colorimetric method Growth inhibition of human RXF631L cells by sulforhodamine B colorimetric method	[PMID: 23313638]
SF-268	GI₅₀	4.9 nM Compound: 5, FK228	Cytotoxicity against human SF268 cells by SRB assay Cytotoxicity against human SF268 cells by SRB assay	[PMID: 24589486]
SF-268	GI₅₀	4.9 nM Compound: 1, FK228	Growth inhibition of human SF268 cells by sulforhodamine B colorimetric method Growth inhibition of human SF268 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
SF-295	GI₅₀	4 nM Compound: 5, FK228	Cytotoxicity against human SF295 cells by SRB assay Cytotoxicity against human SF295 cells by SRB assay	[PMID: 24589486]
SF-295	GI₅₀	4 nM Compound: 1, FK228	Growth inhibition of human SF295 cells by sulforhodamine B colorimetric method Growth inhibition of human SF295 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
SF-539	GI₅₀	3.6 nM Compound: 5, FK228	Cytotoxicity against human SF539 cells by SRB assay Cytotoxicity against human SF539 cells by SRB assay	[PMID: 24589486]
SF-539	GI₅₀	3.6 nM Compound: 1, FK228	Growth inhibition of human SF539 cells by sulforhodamine B colorimetric method Growth inhibition of human SF539 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
SK-OV-3	GI₅₀	3.3 nM Compound: 5, FK228	Cytotoxicity against human SKOV3 cells by SRB assay Cytotoxicity against human SKOV3 cells by SRB assay	[PMID: 24589486]
SK-OV-3	GI₅₀	3.3 nM Compound: 1, FK228	Growth inhibition of human SKOV3 cells by sulforhodamine B colorimetric method Growth inhibition of human SKOV3 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
SNB-75	GI₅₀	7.2 nM Compound: 5, FK228	Cytotoxicity against human SNB75 cells by SRB assay Cytotoxicity against human SNB75 cells by SRB assay	[PMID: 24589486]
SNB-75	GI₅₀	7.2 nM Compound: 1, FK228	Growth inhibition of human SNB75 cells by sulforhodamine B colorimetric method Growth inhibition of human SNB75 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
SNB-78	GI₅₀	9.6 nM Compound: 5, FK228	Cytotoxicity against human SNB78 cells by SRB assay Cytotoxicity against human SNB78 cells by SRB assay	[PMID: 24589486]
SNB-78	GI₅₀	9.6 nM Compound: 1, FK228	Growth inhibition of human SNB78 cells by sulforhodamine B colorimetric method Growth inhibition of human SNB78 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
St-4	GI₅₀	22 nM Compound: 5, FK228	Cytotoxicity against human St-4 cells by SRB assay Cytotoxicity against human St-4 cells by SRB assay	[PMID: 24589486]
St-4	GI₅₀	22 nM Compound: 1, FK228	Growth inhibition of human St-4 cells by sulforhodamine B colorimetric method Growth inhibition of human St-4 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
T-cell	EC₅₀	0.003 μM Compound: Romidepsin, istodax	Reactivation of latent HIV1 NL4-3-Luc expression in human naive CD4+ T cells treated 7 days post-infection measured after 48 hrs by luminescence plate reader analysis Reactivation of latent HIV1 NL4-3-Luc expression in human naive CD4+ T cells treated 7 days post-infection measured after 48 hrs by luminescence plate reader analysis	[PMID: 24495105]
U-251	GI₅₀	3.9 nM Compound: 5, FK228	Cytotoxicity against human U251 cells by SRB assay Cytotoxicity against human U251 cells by SRB assay	[PMID: 24589486]
U-251	GI₅₀	3.9 nM Compound: 1, FK228	Growth inhibition of human U251 cells by sulforhodamine B colorimetric method Growth inhibition of human U251 cells by sulforhodamine B colorimetric method	[PMID: 23313638]
U-937	GI₅₀	3.41 nM Compound: 1, FK228	Antiproliferative activity against human U937 cells after 72 hrs by CCK8 assay Antiproliferative activity against human U937 cells after 72 hrs by CCK8 assay	[PMID: 26331334]
WI-38	GI₅₀	5.39 nM Compound: 1, FK228	Antiproliferative activity against human WI38 cells after 72 hrs by CCK8 assay Antiproliferative activity against human WI38 cells after 72 hrs by CCK8 assay	[PMID: 26331334]

體外研究
(In Vitro)

Romidepsin (0-72 hours；0 -80 nM) 以劑量依賴性方式抑制 HCC 細胞增殖^[2]。
Romidepsin (0-48 hours；0-60 nM) 導致在 HCC 細胞中以時間和劑量依賴性方式誘導 G2/M 期細胞周期停滯^[2]。
Romidepsin (0-48 小時；0-60 nM) 在 HCC 細胞中促進細胞凋亡，增加 c-caspase-3、c-caspase-9 和 c-PARP 蛋白的表達^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[2]

Cell Line:	HCC cells
Concentration:	0 nM; 10 nM; 20 nM; 30 nM; 40 nM; 50 nM; 60 nM; 70 nM; 80 nM
Incubation Time:	0 hours; 12 hours; 24 hours; 48 hours; 72 hours
Result:	Inhibited HCC cells proliferation.

Cell Cycle Analysis^[2]

Cell Line:	HCC cells
Concentration:	0 nM; 15 nM; 30 nM; 60 nM
Incubation Time:	12 hours;24 hours; 48 hours
Result:	Caused a G2/M arrest.

Western Blot Analysis^[2]

Cell Line:	HCC cells
Concentration:	0 nM; 15 nM; 30 nM; 60 nM
Incubation Time:	12 hours;24 hours; 48 hours
Result:	Increaesd c-caspase-3, c-caspase-9, and c-PARP expression in HCC cells.

體內研究
(In Vivo)

Romidepsin (腹腔注射；0.5 和 1 mg/kg；每 3 天一次；21 天) 抑制腫瘤生長，顯示 p-cdc25C、ki67、c-caspase-3 和 c-PARP 的高表達，以及降低腫瘤中 Ki-67 的表達^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nude mice with Huh7 cells^[2]
Dosage:	0.5 and 1 mg/kg
Administration:	Intraperitoneal injection; 0.5 and 1 mg/kg; every 3 day; 21 days
Result:	Suppressed tumor growth in mouse xenograft models.

Clinical Trial

分子量

540.70

Formula

C₂₄H₃₆N₄O₆S₂

CAS 號

128517-07-7

性狀

固體

顏色

White to off-white

中文名稱

羅米地辛

運輸條件

Room temperature in continental US; may vary elsewhere.

儲存方式

Powder	-20°C	3 years

*該產品在溶液狀態(tài)不穩(wěn)定，建議您現(xiàn)用現(xiàn)配，即刻使用。

溶解性數據

細胞實驗：

DMSO 中的溶解度 : ≥ 100 mg/mL (184.95 mM; 吸濕的 DMSO 對產品的溶解度有顯著影響，請使用新開封的 DMSO)

* "≥" means soluble, but saturation unknown.

配制儲備液

濃度溶劑體積質量	1 mg	5 mg	10 mg

1 mM	1.8495 mL	9.2473 mL	18.4945 mL
5 mM	0.3699 mL	1.8495 mL	3.6989 mL
10 mM	0.1849 mL	0.9247 mL	1.8495 mL

查看完整儲備液配制表

* 請根據產品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液；該產品在溶液狀態(tài)不穩(wěn)定，建議您現(xiàn)用現(xiàn)配，即刻使用。

摩爾計算器
稀釋計算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

濃度 _(start)

體積 _(start)

濃度 _(final)

體積 _(final)

動物實驗：

請根據您的實驗動物和給藥方式選擇適當的溶解方案。

以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液，再依次添加助溶劑：
——為保證實驗結果的可靠性，澄清的儲備液可以根據儲存條件，適當保存；體內實驗的工作液，建議您現(xiàn)用現(xiàn)配，當天使用；
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

方案一

請依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (3.85 mM); 澄清溶液

此方案可獲得 ≥ 2.08 mg/mL（飽和度未知）的澄清溶液。
以 1 mL 工作液為例，取 100 μL 20.8 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水定容至 1 mL。
生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
方案二

請依序添加每種溶劑： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (3.85 mM); 懸濁液; 超聲助溶

此方案可獲得 2.08 mg/mL的均勻懸濁液，懸濁液可用于口服和腹腔注射。
以 1 mL 工作液為例，取 100 μL 20.8 mg/mL 的澄清 DMSO 儲備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液中，混合均勻。
2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。
方案三

請依序添加每種溶劑： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (3.85 mM); 澄清溶液

此方案可獲得 ≥ 2.08 mg/mL（飽和度未知）的澄清溶液，此方案實驗周期在半個月以上的動物實驗酌情使用。
以 1 mL 工作液為例，取 100 μL 20.8 mg/mL 的澄清 DMSO 儲備液加到 900 μL玉米油中，混合均勻。

動物溶解方案計算器

請輸入動物實驗的基本信息：

給藥劑量

mg/kg

動物的平均體重

每只動物的給藥體積

μL

動物數量

只

由于實驗過程有損耗，建議您多配一只動物的量

請輸入您的動物體內配方組成：

DMSO +

Tween-80 +

Saline

如果您的動物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。

方案所需 助溶劑 包括：DMSO，，均可在 MCE 網站選購。，Tween 80，均可在 MCE 網站選購。

計算結果

工作液所需濃度 : mg/mL

儲備液配制方法 : mg 藥物溶于 μL DMSO（母液濃度為 mg/mL）。

*該產品在溶液狀態(tài)不穩(wěn)定，建議您現(xiàn)用現(xiàn)配，即刻使用。

您所需的儲備液濃度超過該產品的實測溶解度，以下方案僅供參考，如有需要，請與 MCE 中國技術支持聯(lián)系。

動物實驗體內工作液的配制方法 : 取 μL DMSO 儲備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。

連續(xù)給藥周期超過半月以上，請謹慎選擇該方案。

請確保第一步儲備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱（超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。

純度 & 產品資料

純度: 99.98%

選擇批次：

Data Sheet (649 KB) SDS (394 KB)

COA (210 KB) HNMR (211 KB) LCMS (139 KB)

產品使用指南 (1538 KB)

參考文獻

[1]. Furumai R, et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 2002 Sep 1;62(17):4916-21. [Content Brief]

[2]. Sun WJ, et al. Romidepsin induces G2/M phase arrest via Erk/cdc25C/cdc2/cyclinB pathway and apoptosis induction through JNK/c-Jun/caspase3 pathway in hepatocellular carcinoma cells. Biochem Pharmacol. 2017 Mar 1;127:90-100. [Content Brief]

Romidepsin 相關分類

完整儲備液配制表

* 請根據產品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液；該產品在溶液狀態(tài)不穩(wěn)定，建議您現(xiàn)用現(xiàn)配，即刻使用。

可選溶劑	濃度溶劑體積質量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.8495 mL	9.2473 mL	18.4945 mL	46.2364 mL
	5 mM	0.3699 mL	1.8495 mL	3.6989 mL	9.2473 mL
	10 mM	0.1849 mL	0.9247 mL	1.8495 mL	4.6236 mL
	15 mM	0.1233 mL	0.6165 mL	1.2330 mL	3.0824 mL
	20 mM	0.0925 mL	0.4624 mL	0.9247 mL	2.3118 mL
	25 mM	0.0740 mL	0.3699 mL	0.7398 mL	1.8495 mL
	30 mM	0.0616 mL	0.3082 mL	0.6165 mL	1.5412 mL
	40 mM	0.0462 mL	0.2312 mL	0.4624 mL	1.1559 mL
	50 mM	0.0370 mL	0.1849 mL	0.3699 mL	0.9247 mL
	60 mM	0.0308 mL	0.1541 mL	0.3082 mL	0.7706 mL
	80 mM	0.0231 mL	0.1156 mL	0.2312 mL	0.5780 mL
	100 mM	0.0185 mL	0.0925 mL	0.1849 mL	0.4624 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

產品名稱：			* 需求量：
* 客戶姓名：			* Email：
* 電話：			* 公司或機構名稱：
留言給我們：

產品名稱：			* Lot #：
* 客戶姓名：			* Email：
電話：			* 部門：
* 公司或機構名稱：
留言給我們：

MedChemExpress (MCE) 只為有資質的科研機構、醫(yī)藥企業(yè)基于科學研究或藥證申報的用途提供醫(yī)藥研發(fā)服務，不為任何個人或者非科研性質的、非用于藥證申報使用等其他用途提供服務。	站點地圖隱私聲明
滬ICP備15051369號-4 上海工商滬公網安備31011502019417 滬(浦)應急管危經許[2021]201709(QFYS) 營業(yè)執(zhí)照（三證合一）
Copyright ? 2013-2025 MedChemExpress. All Rights Reserved.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Romidepsin (Synonyms: 羅米地辛; FK 228; FR 901228; NSC 630176)

Customer Review

MCE 顧客使用本產品發(fā)表的 51 篇科研文獻

Romidepsin 相關產品

•相關化合物庫:

•同靶點產品:

•同靶點蛋白產品:

查看 HDAC 亞型特異性產品:

生物活性

純度 & 產品資料

參考文獻

摩爾計算器

稀釋計算器

Romidepsin 相關分類

完整儲備液配制表

Keywords:

您最近查看的產品:

熱門區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
郵箱 *

Sorry, but the email address you supplied was invalid.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Romidepsin (Synonyms: 羅米地辛; FK 228; FR 901228; NSC 630176)

Customer Review

Romidepsin 相關抗體

MCE 顧客使用本產品發(fā)表的 51 篇科研文獻

Romidepsin 相關產品

•相關化合物庫:

•同靶點產品:

•同靶點蛋白產品:

查看 HDAC 亞型特異性產品:

生物活性

純度 & 產品資料

參考文獻

Romidepsin 相關抗體:

摩爾計算器

稀釋計算器

Romidepsin 相關分類

完整儲備液配制表

Keywords:

您最近查看的產品:

Request for HNMR Report

Request for HNMR Report

熱門區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z